Dalfampridine
How it works: Treating relapses and symptoms →
Fampyra
EU: Approved in the EU since 2011US: FDA approved 2010
- Other names
- fampridine
- Molecule type
- Small molecule
- Mechanism (ChEMBL)
- Voltage-gated potassium channel blocker
- Targets
- Voltage-gated potassium channel
- Availability
- Authorised in all EU and EEA countries. Reimbursement is decided by each country.
Approvals
Safety communications
None recorded.
Most-reported side effects (FDA reports)
Reports to the FDA's adverse event system (FAERS) show what people and doctors reported while taking the medicine. They do not prove the medicine caused it, and they are not rates.
74,058 reports in total, 21,758 marked serious.
- Gait disturbance11,184
- Drug ineffective8,493
- Fall7,624
- Fatigue5,692
- Balance disorder5,007
- Multiple sclerosis relapse4,899
- Therapy cessation4,619
- Dizziness4,138
- Urinary tract infection3,885
- Asthenia3,600
Trials
Key trials
Large trials with a reported result on their main goal.
- Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthal
Terminated · Phase 3 · MS (type not specified) · Stopped: not working
- Efficacy and Safety Study of Prolonged-Release Fampridine in Participa
Completed · Phase 3 · Relapsing and progressive · Met its main goal
- Effects of Dalfampridine on Cognition in Multiple Sclerosis
Completed · Phase 2 / Phase 3 · MS (type not specified) · Missed its main goal
- Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
Completed · Phase 3 · MS (type not specified) · Missed its main goal
- Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Completed · Phase 3 · MS (type not specified) · Met its main goal
- Study of Oral Fampridine-SR in Multiple Sclerosis
Completed · Phase 3 · MS (type not specified) · Met its main goal
Running now
- Dalfampridine Combined With Physical Therapy for Mobility Impairment i
Recruiting · Phase 3 · MS (type not specified) · Still running
Other trials (36)
Completed small trials, dose-finding studies and trials in other diseases.
- Fampridine-SR and Optic Neuritis Recovery
Status unknown · Early phase 1 · Optic neuritis · No results found
- New strategies for diagnostic, therapeutic and clinical care in neurol
Status unknown · Phase 4 · MS (type not specified) · No results found
- Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Sp
Completed · Not a drug-phase study · MS (type not specified) · Paper found, not read
- Fampridine in MS Patients: A Cognition, Fatigue, Depression and Qualit
Completed · MS (type not specified) · Paper found, not read
- Effects of dalfampridine on mobility in the context of daily life
Completed · Phase 4 · MS (type not specified) · No results found
- Fampridine Pregnancy Exposure Registry
Terminated · MS (type not specified) · Stopped
- Study and Treatment of Visual Dysfunction and Motor Fatigue in Multipl
Completed · Phase 2 · MS (type not specified) · Missed its main goal
- Study to evaluate the effects of fampridine in patients with multiple
Completed · Phase 2 · MS (type not specified) · Met its main goal
- Efficacy of Dalfampridine on Upper Extremity Function in Patients With
Status unknown · Phase 4 · MS (type not specified) · Paper found, not read
- Resistance Training and Amino Pyridine in Multiple Sclerosis
Completed · Phase 4 · Relapsing and progressive · No results found
For information only, not medical advice. Talk to your neurologist before changing treatment.
Hypotheses involving this medicine
Loading hypotheses…
Loading reviews and guidelines…
Lab studies
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…